Anticoagulant and Antithrombotic Drugs Rivaroxaban CAS 366789-02-8

• Customization: Available
• Powder: Yes
• Customized: Non-Customized
• Model NO.: Rivaroxaban
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Product Name: Rivaroxaban
• CAS No.: 366789-02-8
• Mf: C19h18cln3o5s
• MW: 435.88
• Sample: Available
• Shipping: Prompt Delivery
• Transport Package: Foil Bag
• Specification: 1kg/bag
• Trademark: Senwayer
• Origin: Wuhan, China
• HS Code: 29224995
• Production Capacity: 5000 PCS Per Year

Product Description

Anticoagulant and antithrombotic drugs Rivaroxaban CAS 366789-02-8

 

Product Name	Rivaroxaban
CAS No.	366789-02-8
Molecular formula	C19H18ClN3O5S
Molecular weight	435.88
Purity	98%

 Rivaroxaban is an oral, bioavailable factor Xa inhibitor that selectively blocks the active site of factor Xa and does not require cofactors (such as antithrombin III) to exert its activity. Factor X is activated by endogenous and exogenous pathways as factor Xa (FXa), which plays an important role in the coagulation cascade.
 
Rivaroxaban inhibits the activity of factor Xa in a dose-dependent manner in humans. The prothrombin time (PT) and activated partial thromboplastin time (aPTT) measured by Neoplastin® reagent and the quantitative detection of HepTest® heparin showed a dose-dependent prolongation. The anti-Xa factor activity is also affected by rivaroxaban.

 

New anticoagulants were first used for thrombosis prevention after orthopedic surgery, including total hip and knee replacement surgery, and studies have reported that their effectiveness and safety are not inferior to low-molecular-weight heparin. Nowadays, new anticoagulants are gradually being widely used in the treatment of lower extremity venous thrombosis and pulmonary embolism. In 2014, the latest guidelines for the diagnosis and treatment of acute pulmonary embolism formulated by the ESC mentioned that new anticoagulants can be used as an emerging anticoagulant. Instead of traditional anticoagulation treatments, it will gradually be promoted in high-risk cardiovascular diseases such as atrial fibrillation and acute coronary syndrome.